21. Novel Therapeutic Approaches for Treating Bipolar Disorder

  1. Hagop S. Akiskal2 and
  2. Mauricio Tohen3
  1. Rodrigo Machado-Vieira,
  2. Ioline Henter,
  3. Jacqueline Baumann,
  4. David Latov,
  5. Cristina Wheeler-Castillo and
  6. Carlos A. Zarate

Published Online: 14 APR 2011

DOI: 10.1002/9780470975114.ch21

Bipolar Psychopharmacotherapy: Caring for the Patient, Second Edition

Bipolar Psychopharmacotherapy: Caring for the Patient, Second Edition

How to Cite

Machado-Vieira, R., Henter, I., Baumann, J., Latov, D., Wheeler-Castillo, C. and Zarate, C. A. (2011) Novel Therapeutic Approaches for Treating Bipolar Disorder, in Bipolar Psychopharmacotherapy: Caring for the Patient, Second Edition (eds H. S. Akiskal and M. Tohen), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470975114.ch21

Editor Information

  1. 2

    International Mood Center, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0603, USA

  2. 3

    Department of Psychiatry, Division of Mood and Anxiety Disorders, University of Texas Health Science Centre at San Antonio, 7730 Floyd Curl Drive, San Antonio, TX 78229, USA

Author Information

  1. Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA

Publication History

  1. Published Online: 14 APR 2011
  2. Published Print: 15 APR 2011

ISBN Information

Print ISBN: 9780470747216

Online ISBN: 9780470975114

SEARCH

Keywords:

  • antidepressant;
  • bioenergetics;
  • bipolar disorder;
  • glutamatergic;
  • ketamine;
  • mood disorders;
  • novel therapeutics;
  • purinergic;
  • riluzole

Summary

Existing pharmacological treatments for bipolar disorder (BPD) are in general insufficient for many patients. This chapter reviews a number of targets/compounds that could result in putative novel treatments for BPD. These include: (i) the dynorphin opioid neuropeptide system, (ii) the purinergic system, (iii) the melatonergic system, (iv) the glutamatergic system, (v) the tachykinin neuropeptide system, (vi) the glucocorticoid system, (vii) the arachidonic acid (AA) cascade, (viii) the endocannabinoid system, (ix) oxidative stress and bioenergetics, and (x) intracellular signaling cascades. The compounds reviewed in this chapter have shown either antimanic or antidepressant effects in individuals with BPD, or in preclinical models of mania and depression.